Prenatal and childhood exposure to tobacco smoking was associated with an increased risk for autoimmune disorders.

Tea consumption is associated with higher total hip BMD in older women, while excessive coffee intake may adversely affect BMD.

Early initiation of an intensive blood pressure control reduced the risk for MACE among older patients with hypertension.

The AHA recommended whole exome or whole genome sequencing as first-line diagnostic tools for mitochondrial diseases.

Ultrasound-derived VAT demonstrated better predictive ability than BMI and waist circumference in hepato-metabolic assessment in MASLD.

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

GLP-1RA therapy significantly reduces the risk for new-onset heart failure in patients with T2D or obesity, regardless of weight loss.

Primary hyperparathyroidism is associated with increased long-term risks for hypertension, type 2 diabetes, and cardiovascular disease.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

FDA grants Priority Review to teplizumab for patients aged 1 to 7 years with stage 2 type 1 diabetes to delay stage 3 onset.

For patients at high cardiovascular risk with obesity, semaglutide is associated with reduced burden of total hospital admissions.